109 results about "Ldl chol" patented technology

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts thereof, wherein R¹² is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of—OH and —COOH, and R⁹ contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.

There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

An assay device and method for measuring the concentration of LDL-associated cholesterol in a blood-fluid sample are described. The method employs selective precipitation of VLDL and chylomicrons and immunoseparation of HDL from a blood fluid sample. The assay device allows the assay to be performed entirely in a flow strip fornat.

A method for fractional measurement of small, dense LDL, which is adaptable for an autoanalyzer, and a reagent for measurement, are provided, making it possible to conduct rapid and convenient analysis with good sensitivity without pretreatment of a specimen. The method for quantitatively determining small, dense LDL cholesterol in a sample comprises the steps of:

(1) eliminating cholesterol in LDL other than small, dense LDL in the presence of phospholipase; and

(2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.

Nutritional fat or oil-based compositions for increasing HDL cholesterol, decreasing total cholesterol (TC), LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma are described. The compositions can advantageously include at least 10% of myristic acid and/or lauric acid in which at least 3% of said fatty acid composition is myristic acid and at least 3% is lauric acid; in some cases at least 1% by weight myristic acid and/or lauric acid is esterified at the sn-2 position in triglyceride molecules. The compositions also include between 5% and 40% by weight linoleic acid, and typically further include at least 10% by weight monounsaturated fatty acids and between 15% and 55% by weight total saturated fatty acids. The sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free. Also described are fat compositions and diets which are adapted to limit increases in blood triglycerides, total cholesterol, LDL, and VLDL, even in the presence of dietary cholesterol.

Disclosed are a test strip and a method for measuring medical data. The test strip comprises an upper cover having one or more application holes; a lower support having one or more detected parts at positions corresponding to detecting units of the measuring apparatus; an erythrocyte and LDL cholesterol-filtering layer designed to filter off both of erythrocytes and LDL cholesterol from an applied blood sample by agglutinating erythrocytes and precipitating LDL cholesterol; and a reaction layer in which the blood sample free of erythrocytes and LDL cholesterol is reacted with an reagent, the filtering layer and the reaction layer being stacked between the lower support and the upper cover. Structured to filter off erythrocytes and low-density lipoprotein (LDL) cholesterol from a blood sample in a single layer, the test strip of the present invention can be made to be slim and allows a low volume of blood to be analyzed.

There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition. When the present compositions are administrated into genetically obese mice or high fat diet-induced obese mice, the present compositions reduced body weight, body fat and gonadal fat, and reduce blood cholesterol level and obesity-related blood glucose level. Also, the present compositions suppress hypertrophy of adipocytes, and inhibit the accumulation of lipid in the liver by reducing the size and number of lipid vacuoles. Furthermore, in human clinial trial the present compositions show that body weight, PIBW, body fat, especially visceral fat, apolipoprotin B concentration, ratio of total cholesterol/HDL cholesterol and ratio of LDL cholesterol/HDL cholesterol are significantly decreased, and atherogenic index is improved and muscle mass is increased. Thus, the present compositions can be usefully applied as antiobesity composition for reduction of body weight and suppression of abdominal fat, particularly, visceral fat.

A method for the prevention of dementia is provided including the steps of testing, in a client, for a dementia risk factors (including those related to brain tissue, atrial fibrillation, hypercoaguable state, LDL cholesterol, carotid artery evaluation, tobacco use, hypertension, and inflammation evaluation), determining a score for each of the risk factors tested, wherein each score is based on a continuous scale from a low number to a high number, wherein a low number corresponds to a relatively low likelihood of dementia risk and a high number corresponds to a relatively low likelihood of dementia risk, applying all of the scores obtained to an equation that yields a resulting value proportional to an overall risk of dementia, and providing dementia risk reduction advice to the client to lower the scores for each of the components.

A pharmaceutical composition and method for modifying levels of cholesterol is described. Implementations of a pharmaceutical composition may comprise milk thistle and one of niacin, policosanol, and both niacin and policosanol. Implementations of a pharmaceutical composition may be administered using a method for reducing total cholesterol, LDL cholesterol, and triglycerides and increasing HDL cholesterol levels in a human or animal. The method may include the step of administering a pharmaceutically effective amount of a pharmaceutical composition that includes milk thistle and one of niacin, policosanol, and both niacin and policosanol to a human or animal.

The invention relates to a flavone compound using 3- to replace oxygen radical -3 and 4- dimethoxy and having the function of reducing blood fat, belonging to the technical field of medicine. The chemical construction is like the general formula I; wherein, R stands for H, alhyl radical and acyl radical. Shown by animal experiments, the flavone compound has the function of reducing the triglyceride of serum, the cholesterol and the cholesterol level of LDL and can thus prepare into the medicine or health-caring food for treating or preventing cardiovascular diseases such as hyperlipemia, coronary heart disease and atherosclerosis.

A nutritional fat or oil-based composition for increasing HDL cholesterol, decreasing LDL cholesterol and decreasing the LDL/HDL cholesterol ratio in human plasma is described. The composition typically includes at least 1% by weight myristic acid esterified at the sn-2 position in triglyceride molecules, includes between 10% and 40% by weight linoleic acid, and further includes between 30% and 65% by weight oleic acid and between 15% and 40% by weight total saturated fatty acids. The ratio of sn-2 myristic acid to sn-2 palmitic acid is typically greater than 1:1 and the sum of weight percentages for saturated, monounsaturated and polyunsaturated fatty acids equals 100%. In desirable cases, the composition is substantially cholesterol-free.

Compositions and methods for treating hyperlipidemia and elevated LDL cholesterol and for weight reduction are disclosed. The compositions comprise

• • (a) choline, or a salt or hydroxide thereof;
  • (b) niacin, or a salt, amide or ester thereof;
  • (c) folic acid, or a salt thereof;
  • (d) methionine or a salt or ester thereof; and
  • (e) glycine or a salt, ester or methylated form thereof.

The invention belongs to the technical field of medicines, and relates to a phenylindole derivative and application thereof.The phenylindole derivative comprises stereisomer and pharmaceutically-applicable salt of a phenylindole compound and has the structural formula (please see the formula in the description).The phenylindole derivative and the acid-added pharmaceutically-applicable salt of the phenylindole compound can be used in cooperation with existing medicines or used independently as an estrogen receptor regulator for treating or preventing various diseases related to estrogen functions such as bone loss, fractures, bone rarefaction, hectic fever, LDL cholesterol level rise, cardiovascular diseases, cognitive deficits, brain degeneration diseases, anxiety, depression caused by estrogen deficiency, sexual dysfunction, hypertension, retinal degeneration, cancers and especially osteoporosis.